The Value of a Cure: Ensuring Access and Encouraging Innovation

Innovations in medical research and technology have produced cures and breakthrough therapies to overcome diseases that were once considered a death sentence. Polio is preventable with a vaccine, HIV is managed with a daily drug regimen, and Hepatitis C now has a cure.

But are these breakthroughs reaching all communities? How can we balance the high costs of drug development with affordability? And what can we do to ensure that new cures continue to be developed?

Following the passage of the long-awaited 21st Century Cures legislation, and at the start of a new Congress and new administration, The Hill convened for a conversation with policymakers, health officials, industry representatives and patient advocates on the value of cures - their implications for society's health and public expenditures, and the path forward.


  • Rep. Diana DeGette (D-CO), Member, House Committee on Energy and Commerce
  • Rep. Fred Upton (R-MI), Former Chairman, House Committee on Energy and Commerce
  • Georges Benjamin, MD, Executive Director, American Public Health Association
  • Douglas Dieterich, MD, Director, Institute for Liver Medicine, Professor of Medicine, Division of Liver Diseases, Mount Sinai Health Systems
  • Dana Goldman, PhD, Leonard D. Schaeffer Chair and a Distinguished Professor of Pharmacy, Public Policy & Economics, University of Southern California
  • Garth Graham, MD, President, Aetna Foundation
  • Jim Meyers, Executive Vice President, Worldwide Commercial Operations, Gilead Sciences, Inc.
  • Carmen Pastor, President, Fuerza Contra Alzheimer's
  • Timothy Wright, MD, Chief R&D Officer, Regulus Therapeutics


  • Bob Cusack, Editor-in-Chief, The Hill
  • Peter Sullivan, Staff Writer, The HillĀ